surufatinib
surufatinib: 5 clinical trials tracked.
surufatinib evidence translation
What we can confirm
5 tracked trials
What it means
What to watch
Prepared research question
What is verified about surufatinib, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (5)
Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study
Primary endpoint: PFS
An Open-Label, Multi-Center Phase II Study of Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Patients With Extensive-Stage Small Cell Lung Cancer
Primary endpoint: Progression-free survival
Pamiparib in Combination With Surufatinib in Patients With Platinum-resistant Ovarian Cancer Who Received Prior Poly (ADP-ribose) Polymerase (PARP) Inhibitors: a Multicenter, Single-arm, Phase Ib/II Trial
Primary endpoint: Recommended Phase 2 dose (RP2D) (Phase Ib)
An Open-Label Study of Surufatinib in Japanese Patients With Neuroendocrine Tumors
Primary endpoint: Part 1: Incidence of treatment-emergent adverse events (TEAEs) graded by the Investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v5.0).
An Open-Label Phase 2 Study of Surufatinib in Patients With Neuroendocrine Tumours in Europe
Primary endpoint: Disease Control Rate (DCR)